Xiaoqin Liu1, Natalie C Momen2, Nina Molenaar3, Anna-Sophie Rommel3, Veerle Bergink3, Trine Munk-Olsen2. 1. NCRR-The National Centre for Register-based Research, Aarhus University, Aarhus, Denmark. Electronic address: lxq@econ.au.dk. 2. NCRR-The National Centre for Register-based Research, Aarhus University, Aarhus, Denmark. 3. Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Abstract
BACKGROUND: Several national guidelines include recommendations for a minimum duration of antidepressant treatment, but these vary from 4-9 months after remission. We aimed to investigate whether there is an optimal minimum duration of antidepressant treatment to reduce relapse risk. METHODS: A Danish population-based cohort study among 89,442 adults who initiated antidepressants for depression treatment aged 18-60 years, from 2006-2015. We defined antidepressant discontinuation as ≥30 days without treatment. We estimated hazard ratios (HRs) with 95% confidence intervals (CIs) to indicate the risk of restarting antidepressants among those who discontinued antidepressants with <4, 4-6, and 7-9 months of use compared with discontinuation after 10-12 months. RESULTS: For individuals on antidepressant treatment <4, 4-6, 7-9 and 10-12 months, cumulative incidence of restarting treatment within one year was 37.4% (95% CI: 36.9-37.8%), 35.1% (95% CI: 34.6-35.7%), 35.0% (95% CI: 34.2-35.8%) and 32.8% (95% CI: 31.7-34.0%), respectively. Individuals on antidepressants <10 months versus 10-12 months had higher risk of restarting antidepressants: the HR for antidepressant treatment <4 months was 1.21 (95% CI: 1.16-1.27), 4-6 months 1.11 (95% CI: 1.06-1.17), and 7-9 months 1.09 (95% CI: 1.04-1.15). LIMITATIONS: We were not able to ascertain the reasons why individuals discontinued antidepressants, and systematic errors from unmeasured confounders cannot be ruled out. CONCLUSIONS: Based on our findings, a minimum of 10-12 months of treatment appears to be preferable if there is concern about relapse after discontinuation.
BACKGROUND: Several national guidelines include recommendations for a minimum duration of antidepressant treatment, but these vary from 4-9 months after remission. We aimed to investigate whether there is an optimal minimum duration of antidepressant treatment to reduce relapse risk. METHODS: A Danish population-based cohort study among 89,442 adults who initiated antidepressants for depression treatment aged 18-60 years, from 2006-2015. We defined antidepressant discontinuation as ≥30 days without treatment. We estimated hazard ratios (HRs) with 95% confidence intervals (CIs) to indicate the risk of restarting antidepressants among those who discontinued antidepressants with <4, 4-6, and 7-9 months of use compared with discontinuation after 10-12 months. RESULTS: For individuals on antidepressant treatment <4, 4-6, 7-9 and 10-12 months, cumulative incidence of restarting treatment within one year was 37.4% (95% CI: 36.9-37.8%), 35.1% (95% CI: 34.6-35.7%), 35.0% (95% CI: 34.2-35.8%) and 32.8% (95% CI: 31.7-34.0%), respectively. Individuals on antidepressants <10 months versus 10-12 months had higher risk of restarting antidepressants: the HR for antidepressant treatment <4 months was 1.21 (95% CI: 1.16-1.27), 4-6 months 1.11 (95% CI: 1.06-1.17), and 7-9 months 1.09 (95% CI: 1.04-1.15). LIMITATIONS: We were not able to ascertain the reasons why individuals discontinued antidepressants, and systematic errors from unmeasured confounders cannot be ruled out. CONCLUSIONS: Based on our findings, a minimum of 10-12 months of treatment appears to be preferable if there is concern about relapse after discontinuation.
Authors: Sidney H Kennedy; Raymond W Lam; Roger S McIntyre; S Valérie Tourjman; Venkat Bhat; Pierre Blier; Mehrul Hasnain; Fabrice Jollant; Anthony J Levitt; Glenda M MacQueen; Shane J McInerney; Diane McIntosh; Roumen V Milev; Daniel J Müller; Sagar V Parikh; Norma L Pearson; Arun V Ravindran; Rudolf Uher Journal: Can J Psychiatry Date: 2016-08-02 Impact factor: 4.356
Authors: Silvana Borges; Yeh-Fong Chen; Thomas P Laughren; Robert Temple; Hiren D Patel; Paul A David; Mitchell Mathis; Ellis Unger; Peiling Yang; Ni A Khin Journal: J Clin Psychiatry Date: 2014-03 Impact factor: 4.384
Authors: Scott A Bull; X Henry Hu; Enid M Hunkeler; Janelle Y Lee; Eileen E Ming; Leona E Markson; Bruce Fireman Journal: JAMA Date: 2002-09-18 Impact factor: 56.272
Authors: Evelyn Bromet; Laura Helena Andrade; Irving Hwang; Nancy A Sampson; Jordi Alonso; Giovanni de Girolamo; Ron de Graaf; Koen Demyttenaere; Chiyi Hu; Noboru Iwata; Aimee N Karam; Jagdish Kaur; Stanislav Kostyuchenko; Jean-Pierre Lépine; Daphna Levinson; Herbert Matschinger; Maria Elena Medina Mora; Mark Oakley Browne; Jose Posada-Villa; Maria Carmen Viana; David R Williams; Ronald C Kessler Journal: BMC Med Date: 2011-07-26 Impact factor: 8.775
Authors: Michael F Hvidberg; Søren P Johnsen; Charlotte Glümer; Karin D Petersen; Anne V Olesen; Lars Ehlers Journal: Scand J Public Health Date: 2016-04-20 Impact factor: 3.021